At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
Routine meropenem therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients
In Brief
A Phase 4 clinical trial evaluating Routine meropenem therapy and Meropenem therapy based on a PPK and PD model for Lower Respiratory Tract Infection. Completed, enrolled 79 participants across 1 site.
Detailed Summary
To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLower Respiratory Tract Infection
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedSep 2013
Primary CompletionOct 2015
TodayJul 2026
First PostedSep 17, 2013
Enrollment StartJul 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.8 years ago
Interventions
Routine meropenem therapydrug
Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
Meropenem therapy based on a PPK and PD modeldrug
Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model